SCHEMBL4470516

SCHEMBL4470516

CCOC(=O)c1cc(O)c2ccc(C(F)(F)F)cc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
HSP90AA1 P07900 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
THRB P10828 1/20 0.45
MAOB P27338 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
ALOX5 P09917 1/20 0.43
CYP1A2 P05177 1/20 0.42
PDE6D O43924 1/20 0.41
PDE5A O76074 1/20 0.41
PDE6A P16499 1/20 0.41
PDE6G P18545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9998041 0.90 KDM4E (0.52) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL4482350 0.86 PDE5A (0.47) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL2910799 0.86 CFTR (0.49) KDM4EALDH1A1MEN1MAPTKMT2A
SCHEMBL3332188 0.83 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL3328767 0.81 ALDH1A1 (0.48) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL31167429 0.81 ALDH1A1 (0.48) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL2904601 0.80 IGFBP3 (0.50) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL3336367 0.80 ALDH1A1 (0.54) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL20558 0.79 KDM4E (0.47) KDM4EALDH1A1HPGDHSD17B10MEN1
SCHEMBL21660 0.79 MAPT (0.47) KDM4EALDH1A1HPGDHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553848-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-06-30 US disclosed
EP-1725529-A1 BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN Amgen Inc. (US) 2006-11-29 EP disclosed
WO-2005070885-A1 BIS BICYCLIC AMIDES AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS OF INFLAMMATORY AND NEUROPATIC PAIN AMGEN INC. (US) 2005-08-04 WO disclosed
US-20050165046-A1 Vanilloid receptor ligands and their use in treatments AMGEN, INC. 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165046-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KDM4E 3989/4885ALDH1A1 3014/4885HPGD 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.